D.E. Shaw & Co
TVGN icon

D.E. Shaw & Co’s Tevogen Inc. Common Stock TVGN Stock Holding History

D.E. Shaw & Co’s Portfolio TVGN Stock Details TVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-15,923
Closed -$8.22M – 4933
2022
Q4 		$8.22M Hold
15,923
– – 0.01% 1618
2022
Q3 		$8.09M Buy
15,923
+5,099
+47% +$2.57M 0.01% 1545
2022
Q2 		$5.42M Buy
10,824
+2,144
+25% +$1.07M 0.01% 2025
2022
Q1 		$4.33M Buy
+8,680
New +$4.32M ﹤0.01% 2481

Other funds holding TVGN

CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co's TVGN Position: Q1 2023 in Review

D.E. Shaw & Co sold out of Tevogen Inc. Common Stock (TVGN) in Q1 2023, closing a stake of 15,923 shares — an estimated $8.22M sold.

D.E. Shaw & Co first reported a position in TVGN in Q1 2022 and held it in 4 quarters. The position peaked at $8.22M in Q4 2022. 4 funds tracked by Wall St. Rank hold TVGN as of Q1 2023.

  • D.E. Shaw & Co reported no remaining Tevogen Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • D.E. Shaw & Co sold 15,923 Tevogen Inc. Common Stock shares in Q1 2023, an estimated $8.22M.
  • D.E. Shaw & Co first reported a position in Tevogen Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • D.E. Shaw & Co's Tevogen Inc. Common Stock position peaked at $8.22M in Q4 2022.
  • 4 funds tracked by Wall St. Rank held Tevogen Inc. Common Stock as of Q1 2023.

Based on D.E. Shaw & Co's 13F filing for Q1 2023, filed 15 May 2023.